Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 227.79M P/E - EPS this Y - Ern Qtrly Grth -
Income -1.47B Forward P/E -1.86 EPS next Y - 50D Avg Chg -9.00%
Sales 27.64M PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 0.08 EPS next 5Y 26.00% 52W High Chg -71.00%
Recommedations 1.80 Quick Ratio 5.55 Shares Outstanding 80.70M 52W Low Chg 5.00%
Insider Own 1.06% ROA -23.11% Shares Float 122.60M Beta 1.11
Inst Own 35.07% ROE -62.02% Shares Shorted/Prior 1.17M/1.07M Price 2.73
Gross Margin 100.00% Profit Margin - Avg. Volume 303,364 Target Price 26.00
Oper. Margin -7,062.80% Earnings Date Mar 14 Volume 484,225 Change -1.44%
About I-MAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

I-MAB News
04/05/24 I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
04/02/24 I-Mab Announces Closing of the Divestiture of Business Operations in China
03/18/24 I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
03/14/24 I-Mab Reports Full Year 2023 Financial Results and Business Update
02/21/24 Q4 2023 Summit Therapeutics Inc Earnings Call
02/07/24 UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US
02/07/24 I-Mab Signs Agreement to Divest its Assets and Business Operations in China
11/19/23 Individual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%
11/06/23 I-Mab Announces Participation at Jefferies and Piper Conferences in November
11/02/23 Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
11/01/23 I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
10/16/23 I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
10/10/23 I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
10/05/23 Ray Dalio on Potential US-China War and Rise of China
09/22/23 UPDATE 1-AbbVie terminates deal with I-Mab to develop cancer drug
09/05/23 I-Mab Announces Upcoming Participation at September Conferences
08/18/23 I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript
08/17/23 Half Year 2023 I-Mab Earnings Call
08/17/23 I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
08/08/23 I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
IMAB Chatroom

User Image AlwaysRational Posted - 2 days ago

$IMAB When was the last time you saw a convergence like this?

User Image Personal_Trading Posted - 6 days ago

$IMAB EDBI Pte Ltd (Singapore) 222,136 shares 4/18.

User Image JAJa82 Posted - 6 days ago

$IMAB

User Image Redzijs92 Posted - 1 week ago

$IMAB Iam out. Good luck guys 💪🏽

User Image JohnTill Posted - 1 week ago

$IMAB @Personal_Trading Just so you do not mislead people too much. Cash was $321 million as of December 31, 2022. They would have used ~$35-40 million in operations to the end of this quarter (March 31), ~30-35 million to be paid to Hangzhou shareholders, ~$19 million for the investment into IMAB China plus I am guessing $4-8+ million extra in restructuring and legal to get all of this done plus the money spent on buybacks (which is not a bad things but eats cash as they give a higher number of shares to employees). So do not be surprised to see ~$215-230 million in cash print on the next quarter with the same 81 million shares outstanding. Is that on point enough for you????

User Image Personal_Trading Posted - 1 week ago

$IMAB The CEO feels the cash position and the burn rate are sufficient to consider in-licensing candidates. That says a lot about the financial status of the company. To reiterate from earlier correspondence. Cash estimate of $321M less $30M that may be paid to non participating Hangzhou shareholders. Estimated annual expenses of $70-$75M (40% of $175M). Market cap of $147M. Shares outstanding 81M.

User Image danip Posted - 1 week ago

$IMAB I ask them about the ADR and the answer: "We are still an ADR, so there is no change at present. We will update you if there are any changes in the future but do not expect that there is a cancellation fee"

User Image Personal_Trading Posted - 1 week ago

$IMAB 23rd annual Needham Healthcare Conference. Givastomig data in the first half of 2024. Ragistomig discussion. Uliledlimab IND submission The company will consider in-licensing candidates. $321 million in cash. No guidance on cash runway until the next earnings report.

User Image Redzijs92 Posted - 1 week ago

$IMAB https://ir.i-mabbiopharma.com/static-files/b5a25c60-499b-430b-8ad0-64f241d07cb9

User Image Redzijs92 Posted - 1 week ago

$IMAB watching conference and it’s look like Joe are in wrong place like random guy go in conference 😂

User Image shortking2022 Posted - 2 weeks ago

$IMAB you sheep do know it’s only a matter of time until they need to raise funding given they gave away all their near term revenue generators and are moving countries. Also, all the China leadership left but no US leadership announced. Ouch. Under $1 incoming

User Image Tika1 Posted - 2 weeks ago

$IMAB I-Mab will be presenting at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024. Our management team will also be available for one-on-one and small group meetings throughout the day. I am looking forward to the upcoming Needham Virtual Healthcare Conference where I-Mab will present for the first time as an American company. I think events like this will lead to a higher valuation for the company, and I am working on my model to establish a reasonable price target.

User Image Stock_Titan Posted - 2 weeks ago

$IMAB I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/IMAB/i-mab-to-participate-at-the-23rd-annual-needham-virtual-healthcare-ow5maugctfal.html

User Image rudy1992 Posted - 2 weeks ago

$IMAB if the divestment is that bad, the price action shouldn’t look like this tho. I feel like something is cooking, but just my two cents

User Image Redzijs92 Posted - 3 weeks ago

$IMAB what you think about news?

User Image Stock_Titan Posted - 3 weeks ago

$IMAB I-Mab Announces Closing of the Divestiture of Business Operations in China https://www.stocktitan.net/news/IMAB/i-mab-announces-closing-of-the-divestiture-of-business-operations-in-imt88rdeco55.html

User Image Personal_Trading Posted - 3 weeks ago

$IMAB Chief Business Officer Weimin Tang, Chief Communications Officer Gigi Qi Feng and Chief Legal Officer Richard Cheng Li have resigned from their respective positions, effective March 31, I-Mab disclosed in an SEC filing. “None of these resignations were due to any disagreement with the Company,” it wrote, adding that it’s searching for a new chief business officer and chief legal officer.

User Image shortking2022 Posted - 3 weeks ago

$IMAB still stands. Although I see he’s quiet these days.

User Image Redzijs92 Posted - 3 weeks ago

$IMAB not really good

User Image Tika1 Posted - 03/28/24

$IMAB We will get update soon. The agreement to divest assets and business operations in China, previously announced in a press release on February 7, 2024, is expected to be completed by the end of March 2024. Upon the closing of the transaction, the Greater China rights for assets including eftansomatropin alfa, felzartamab, uliledlimab, and givastomig will be transferred to I-Mab Biopharma (Hangzhou) Co., Ltd., an unconsolidated affiliate (the "Hangzhou Company"). I-Mab will no longer bear future development costs of these divested assets in China and may receive an aggregate consideration of the RMB equivalent of up to US$80 million, contingent on the Hangzhou Company group's achievement of certain future regulatory and sales-based milestone events relating to these divested assets in China. The transaction, if closed, will also extinguish existing repurchase obligations owed by a wholly-owned subsidiary of the Company in the amount of approximately US$183 million.

User Image Personal_Trading Posted - 03/28/24

$IMAB On March 27, 2024 - Nomura Holdings Inc filed a 13F-HR/A form disclosing ownership of 23,000 shares of I-Mab - Depositary Receipt (Common Stock) (US:IMAB) valued at $43,700 USD as of December 31, 2023. The entity filed a previous 13F-HR on November 14, 2023 disclosing 397,085 shares of I-Mab - Depositary Receipt (Common Stock). This represents a change in shares of -94.21% during the quarter.

User Image RollingDollar Posted - 03/27/24

$IMAB

User Image Stockboi_ Posted - 03/26/24

$IMAB adding

User Image Redzijs92 Posted - 03/26/24

$IMAB look like Iam holding this stock last week. Nothing not happening one cent up one cent down. News long time not see. In one word- boring stock 🤷🏽‍♂️

User Image RollingDollar Posted - 03/26/24

$IMAB

User Image forfun88 Posted - 03/26/24

$IMAB remember when they dumped all their late stage, soon profitable assets by giving it to the new China entity ran by the original founder. #fraud

User Image Tika1 Posted - 03/25/24

@Redzijs92 These days, it seems Chinese companies are being generous. LIAN returned over $500 million to shareholders and closing its door. $LU is giving a 70% dividend ( returning $1.5 billion USD from cash reserve). I also see other profitable Chinese company are increasing divvy or buybacks. $IMAB is decoupling from China and has some very good assets. I don't think it will be able to go it alone all the way by itself. It will likely merge with or sell itself to another company.

User Image Tika1 Posted - 03/25/24

$IMAB What is possibility this company sells all IPs and US right and distribute cash just like $LIAN ? In that case we might get $4-5.

User Image RollingDollar Posted - 1 month ago

$IMAB

User Image TickerDD_com Posted - 1 month ago

From 3/19/2024, looking back across 22 Month-Ends for IMAB, Percentage Change of Average Monthly Price had More Negatives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $IMAB #IMAB #IMABStock #TickerDD https://www.youtube.com/watch?v=fVm99wj1RLk

Analyst Ratings
Needham Buy Apr 12, 24
Piper Sandler Overweight Mar 18, 24
HC Wainwright & Co. Buy Mar 18, 24
Needham Buy Mar 15, 24
Needham Buy Feb 8, 24
Needham Buy Sep 25, 23
Cantor Fitzgerald Overweight Sep 5, 23
Cantor Fitzgerald Overweight Aug 18, 23
HC Wainwright & Co. Buy Aug 18, 23